Johnson Johnson AbbVie: Paths to Pharma Dominance
Johnson & Johnson and AbbVie report divergent quarterly results, fueling a debate about two paths to pharma dominance...
Financial planning is vital for a successful retirement. Discover the reasons why it matters for your long-term financial health.
23,858 articlesJohnson & Johnson and AbbVie report divergent quarterly results, fueling a debate about two paths to pharma dominance...
Netflix faces a pivotal July 16 earnings date. This article breaks down the three main reasons the stock needs convin...
Analysts see value in Nvidia-backed AI infrastructure bets after last week’s pullback, highlighting dip-buy opportuni...
Bitcoin braces for the July CPI report as traders weigh potential Fed tightening. A hotter print could push BTC lower...
LNG demand is reshaping bets on natural gas, lifting producer-focused ETFs while futures-based funds lag. Analysts wa...
BNB Chain completes 36th quarterly burn, marking the third burn of 2026. The auto-burn removed 1.615 million BNB, bri...
Dell shares tumbled about 14% as investors pulled back from AI hardware names, with HPE and Super Micro also sliding....
Space stocks remain volatile, but two names stand out for investors: SpaceX SPCX and Rocket Lab RKLB. This guide brea...
Tesla pushed out a solid delivery quarter, but the stock didn’t follow. This article breaks down what the numbers mea...
Firms across tech and logistics are testing cheaper Chinese AI models as U.S. rivals grow pricier. The move spans sta...
Microsoft stock has fallen about 27% from its all-time high, but long‑term catalysts could help it double by 2030. Th...
NVIDIA disclosed a major reshuffle of its private investments, exiting Arm and Applied Digital and boosting its Intel...